Dengue virus

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Retrieved on: 
Thursday, April 4, 2024
Certification, Plasma, CE, GRFS, Risk, Arbovirus, Climate, RNA, GRF, Fever Dream, IVDR, Chikungunya, Death, Dengue virus, MCE, Blood bank, NAT, Vertically transmitted infection, Medical device

These are the four most significant arboviruses of concern, all spread through mosquito vectors.

Key Points: 
  • These are the four most significant arboviruses of concern, all spread through mosquito vectors.
  • With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1
    Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA.
  • Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.
  • “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit.

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024
Medical Subject Headings, Marketing, Protein, Fever Dream, INN, Risk, Immune system, Infection, Fever, HIV/AIDS, Woman, Virus, ATC, Antibody, Pain, International, Injection, Headache, Disease, Weakness, Ageing, Language, Vaccination, Red, Allergy, European Medicines Agency, HIV, Vaccine, Myalgia, Select, Dengue virus, Patient, Anatomy, IIA, Skin

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Pasteur Network and GeoSeeq Foundation Partner to Tackle Climate-Associated Increases in Infectious Disease

Retrieved on: 
Tuesday, October 31, 2023
Laboratory, Global North and Global South, Infection, Health, Therapy, Pasteur Institute, Physician, Climate, Malaria, Pasteur Institute of Dakar, Genomics, COVID-19, Partnership, Dengue virus, Developing country, Public, Cholera, Canine vector-borne disease, Vaccine, Pharmaceutical industry

PARIS and NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The threat of infectious diseases is constant and far-reaching, killing 14 million people annually. Changes in climate are exacerbating infectious disease threats, especially for water- and vector-borne diseases. These increased infectious disease threats are most often distributed in low- and middle-income countries, which experience annual surges in dengue virus, malaria, cholera and other infections. While prevention is the ideal approach to controlling infectious diseases, there is limited cross-border surveillance and coordination to drive prevention and response. Furthermore, despite recent lessons from the COVID-19 pandemic, there is still no global system for infectious disease monitoring. Instead, existing platforms are siloed and single-modality or single-region focused.

Key Points: 
  • Changes in climate are exacerbating infectious disease threats, especially for water- and vector-borne diseases.
  • "This partnership marks an important step toward unlocking untapped potential across a leading global infectious disease network," said Dr. Rebecca Grais, executive director of Pasteur Network.
  • "This partnership marks an important step toward unlocking untapped potential across a leading global infectious disease network," said Dr. Rebecca Grais, executive director of Pasteur Network.
  • "Too often, groups feel isolated in their fight against infectious diseases," said Dr. Amadou Sall, director general of Institut Pasteur de Dakar and president of Pasteur Network.

ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

Retrieved on: 
Wednesday, June 28, 2023
Vaccine, Urbanization, Human, Dengue fever, Fever, COVID-19, Fever Dream, Infection, Antibody, Incidence, VHH, EUR, Climate change, Disease, Aedes, WHO, Immunodeficiency, Death, Dengue virus

GHENT, Belgium, June 28, 2023 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, today announced it has been awarded a two-year R&D grant of EUR 1.6 million by Flanders Innovation & Entrepreneurship (VLAIO) for pre-clinical research towards prophylactic and therapeutic solutions for dengue.

Key Points: 
  • GHENT, Belgium, June 28, 2023 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, today announced it has been awarded a two-year R&D grant of EUR 1.6 million by Flanders Innovation & Entrepreneurship (VLAIO) for pre-clinical research towards prophylactic and therapeutic solutions for dengue.
  • According to the WHO, dengue is one of the most important vector-borne viral diseases globally that is transmitted from mosquitoes to humans [1].
  • It is caused by any of four dengue virus serotypes, each of which can cause dengue fever, and, in some cases, it can lead to deadly complications such as dengue hemorrhagic fever or dengue shock syndrome.
  • ExeVir is leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against infectious diseases, such as dengue.

Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Tissue, Flaviviridae, Social Mobilisation Network (SMNet), Antibody-dependent enhancement, Clinical trial, Infection, Antibody, Public health, Risk, ADE, Ageing, Memory, Dengue virus, Skin, Safety, Disease, Dengue fever

No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.

Key Points: 
  • No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.
  • From a safety perspective, both doses were considered acceptable for use in further trials.
  • These data demonstrate that our product platform has an acceptable safety profile and successfully mobilises viral-specific CD8+ T cells, which may elicit broad and long-term immune memory.
  • Follow-up of trial participants took place over a six-month period following first injection.

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 12, 2023
Bemnifosbuvir, Truncation, Therapy, Hospital, Virology, Dengue virus, COVID-19, Atea, Pharmacokinetics, Viral, ICAR, QRS, Doctor of Philosophy, QT, QT interval, Plasma, Congress, ECCMID, International Conference on Population and Development, Antiviral Research, Patient, European, Risk, Political moderate, Adolescence, Electrocardiography, Heart rate, Conference, HCV, Infection, Safety, Pharmaceutical industry

These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.

Key Points: 
  • These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark.
  • “The MORNINGSKY data also highlight additional potential clinical benefits of bemnifosbuvir.
  • Adverse events leading to treatment discontinuation were observed in 2.8% of patients treated with bemnifosbuvir compared to 7% of patients receiving placebo.
  • Atea will also present clinical data for AT-752, an oral double prodrug of a guanosine nucleotide analog for the treatment of dengue virus, at ECCMID 2023.

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Retrieved on: 
Tuesday, March 14, 2023
Conference, Na'aran, Viral, RNA-dependent RNA polymerase, International Conference on Emerging Infectious Diseases, CNRS, ICAR, COVID-19, SLC, Rat, Doctor of Philosophy, CYP450, Urine, HIV disease progression rates, Cirrhosis, ABC, Antiviral Research, CET, SP, Drug resistance, Aix-Marseille University, SARS-CoV-2, Fever Dream, NS5A, BEM, Infection, Sulfur, Plasma, GUK1, Risk, ADME, Methylation, Enzyme, Patient, Metabolism, UGT1A1, Coronavirus, Phosphate, Safety, Discovery and development of NS5A inhibitors, RNA, Hepatitis C, Human coronavirus OC43, Combination, Virus, DENV, Maintenance, Architecture, GalNAc-T activation pathway, Feces, HINT1, Orthornavirae, Dengue virus, RZR, Therapy, NS5, Pharmaceutical industry, Vaccine, Flour, Phosphorus, Bemnifosbuvir, HCV

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C (HCV). Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.

Key Points: 
  • Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented.
  • These results are being presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place March 13-17, 2023 in Lyon, France.
  • These advantages include a higher barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.
  • Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions.

Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

Retrieved on: 
Wednesday, March 15, 2023
Science, Biotechnology, Research, Pharmaceutical, Environment, Health, Climate Change, Clinical Trials, CD3, Johnson & Johnson, Lead, Duke–NUS Medical School, Emerging Pathogens Institute, Heidelberg University, NS4B, Tropical medicine, Hospital, Trial of the century, Janssen Pharmaceuticals, Walter Reed Army Institute of Research, NS3, Global health, Viral, Kigali Declaration on Neglected Tropical Diseases, Infection, Aix-Marseille University, Fever Dream, Neglected tropical diseases, University, Artificial intelligence, Mebendazole, Janssen, Mouse, Risk, Drug design, Hope, Dengue fever, Biomedical Primate Research Centre, Leprosy, Society, Hygiene, Climate change, UTMB, Disease, Incidence, Dengue virus, Therapy, Pharmaceutical industry, Vaccine, Nature, Virology

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.

Key Points: 
  • The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.
  • These findings build on research published in Nature in 2021 that first identified the novel mechanism of action from the same chemical series as JNJ-1802.
  • In addition to developing JNJ-1802, Johnson & Johnson is working to holistically strengthen R&D for dengue, including through novel R&D approaches and leveraging emerging technology.
  • You can learn more about Johnson & Johnson’s efforts to beat NTDs, including dengue, by visiting JNJ.com/NTDs .

North America Laboratory Animal Diets Market Report 2022: Growing Consumption of Personalized Medicines Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Other Science, Science, End user, Animal, CRISPR, Infection, Malaria, COVID-19, HIV, Mouse, Precision medicine, Pathology, Government, Knowledge, Dengue virus, Vaccine, Genetics, Biology, Pathogen, Therapy, Drug discovery, Tissue engineering, Center for Urban and Regional Analysis, Research, Cancer, Mycobacterium tuberculosis, Île-de-France Clusters, Plasmodium falciparum, Disulfiram-like drug, Plasmodium, Regenerative medicine, Dietary supplement, Potash, Pharmaceutical industry

The North America laboratory animal diets market is segmented on the basis of diet type, animal, application, end user, and country.

Key Points: 
  • The North America laboratory animal diets market is segmented on the basis of diet type, animal, application, end user, and country.
  • Based on diet type, the North America laboratory animal diets market is segmented into standard diets, irradiated diets, and autoclavable diets.
  • Based on animal, the North America laboratory animal diets market is segmented into mouse, cat, dog, rabbit, chicken, and others.
  • Based on country, the North America laboratory animal diets market is segmented into the US, Canada, and Mexico.

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

Retrieved on: 
Thursday, December 8, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, VE, Infection, Fever Dream, Hospital, Immunization, Anaphylaxis, Headache, Disease, Syncope, Dengue fever, Medication package insert, Woman, Dengue virus, Contraindication, Fiscal, Risk, Vaccination, CHMP, EC, Union, Prednisone, Royal commission, Friends, TAK, Myalgia, Holiday, European Directive on Traditional Herbal Medicinal Products, Climate change, Birth, Immunodeficiency, Hyperventilation, Overalls, Science, Travel, HIV, Excipient, European Medicines Agency, VCD, Patient, Tropical medicine, Hypersensitivity, Incidence, European Commission, Safety, Weakness, Fever, Vaccine, Takeda, EU

Guidance for use: QDENGA should be administered by subcutaneous injection preferably in the upper arm in the region of deltoid.

Key Points: 
  • Guidance for use: QDENGA should be administered by subcutaneous injection preferably in the upper arm in the region of deltoid.
  • Appropriate medical treatment and supervision must always be readily available in the event of a rare anaphylactic reaction following administration of the vaccine.
  • 2020;395:1423-1433.
    x Tricou, V. Efficacy and Safety of Takedas Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up.
  • December 2022.
    xiv Efficacy, Safety and Immunogenicity of Takedas Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES).